| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/29/2008 | WO2008062429A2 Particles for delivery of active ingredients, process of making and compositions thereof |
| 05/29/2008 | WO2008062021A1 Vaginal delivery system for mirtazapine |
| 05/29/2008 | WO2008062009A1 Delivery system for risperidone |
| 05/29/2008 | WO2008062008A1 Delivery system for a non-steroidal non-ionized hydrophilic drug |
| 05/29/2008 | WO2008061963A2 Helically-shaped drug delivery system |
| 05/29/2008 | WO2008061873A2 Stable powder formulation containing a novel anticholinergic agent |
| 05/29/2008 | WO2008061677A1 Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 05/29/2008 | WO2008061639A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 05/29/2008 | WO2008061625A2 Transdermal therapeutic system for administering the active substance buprenorphine |
| 05/29/2008 | WO2008061447A1 A medicine for treating eczema and process of ointment thereof |
| 05/29/2008 | WO2008061409A1 Enteric coated formulation comprising alkaline active agent and its preparation process |
| 05/29/2008 | WO2008061355A1 Glp-1 depot systems, and methods of manufacture and uses thereof |
| 05/29/2008 | WO2008042331A3 Film embedded packaging and method of making same |
| 05/29/2008 | WO2008041246A3 Injectable depot composition and its' process of preparation |
| 05/29/2008 | WO2008036847A3 Self preserved aqueous pharmaceutical compositions |
| 05/29/2008 | WO2008030830A3 Sustained-release composition and method of use thereof |
| 05/29/2008 | WO2008029310A3 Delivery systems for delivering functional compounds to substrates and processes of using the same |
| 05/29/2008 | WO2008027963A3 Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| 05/29/2008 | WO2008027611A3 Compositions for visualization of vitreous body and methods of using same |
| 05/29/2008 | WO2008025111A8 Biodegradable device for intraocular drug delivery |
| 05/29/2008 | WO2008024846A3 Brimonidine and timolol compositions |
| 05/29/2008 | WO2008020820A3 Pharmaceutical compositions comprising aripiprazole |
| 05/29/2008 | WO2008016678A3 Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| 05/29/2008 | WO2008012709A3 Thermochromic compositions for skin application |
| 05/29/2008 | WO2008012367A3 Compositions containing quaternary ammonium compounds |
| 05/29/2008 | WO2008008733A3 Nanoparticulate sorafenib formulations |
| 05/29/2008 | WO2007149334A3 Vegf antagonist formulations suitable for intravitreal administration |
| 05/29/2008 | WO2007146943A3 Nanoparticulate kinase inhibitor formulations |
| 05/29/2008 | WO2007145863A3 Sustained release formulation of naltrexone |
| 05/29/2008 | WO2007138301A3 Novel formulation |
| 05/29/2008 | WO2007127668A3 Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| 05/29/2008 | WO2007124382A3 Inhaled imipenem |
| 05/29/2008 | WO2007123691A3 Method for treating blood coagulation disorders |
| 05/29/2008 | WO2007113665A3 Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides |
| 05/29/2008 | WO2007076053A8 Stable s-nitrosothiol formulations |
| 05/29/2008 | US20080125760 Directional Anchoring Mechanism, Method and Applications Thereof |
| 05/29/2008 | US20080125759 Convection-enhanced drug delivery device and method of use |
| 05/29/2008 | US20080125702 Non-constant pressure infusion pump |
| 05/29/2008 | US20080125482 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 05/29/2008 | US20080125453 Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
| 05/29/2008 | US20080125433 Method of treating hair loss using thyromimetic compounds |
| 05/29/2008 | US20080125422 Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080125356 Stable Growth Hormone Liquid Formulation |
| 05/29/2008 | US20080125351 Forming water-in-oil emulsion from aqueous phase (water soluble polypeptide and sugar) and oil phase comprising glycolic acid-lactic acid copolymer and solvent, adding silicone oil, hardening, drying; optimizing the silicone oil to polymer ratio to improve bioavailability of peptide drug |
| 05/29/2008 | US20080125349 Biocompatible polymer such as glycolic acid-lactic acid copolymer having dispersed therein a polypeptide and a sugar, for release of said peptide such as exendin-4 |
| 05/29/2008 | US20080125348 Biocompatible glycolic acid-lactic acid copolymer with a polypeptide and a sugar; drug delivery of peptide drugs such as exendin-4; improves bioavailability, patient compliance |
| 05/29/2008 | US20080124793 Membrane fusion proteins derived from reoviridae for use in delivery of bioactive drugs to cells |
| 05/29/2008 | US20080124780 Microarray comprising semipermeable matrix for use in monitoring drug metabolism |
| 05/29/2008 | US20080124473 Silk fibroin from domesticated silkworm; sustained release; waste treatment |
| 05/29/2008 | US20080124411 nasal strip; and an orally administered composition comprising a tissue-firming agent, a tissue-soothing agent, a tissue lubricant, and an expectorant; for combating snoring |
| 05/29/2008 | US20080124400 Microparticles With High Loadings Of A Bioactive Agent |
| 05/29/2008 | US20080124399 Such as capsules/beads of cyclobenzaprine hydrochloride |
| 05/29/2008 | US20080124398 Modified release dosage forms of skeletal muscle relaxants |
| 05/29/2008 | US20080124397 Bone pastes; storage under vacuum; mixing using syringes |
| 05/29/2008 | US20080124396 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 05/29/2008 | US20080124395 Formulations and devices for treatment or prevention of neural ischemic damage |
| 05/29/2008 | US20080124394 use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially a peptide in a lipid-based controlled-release matrix; bioadhesive |
| 05/29/2008 | US20080124393 Time-release agent containing poorly soluble agent such as clozapine; release the agent following administration for a time period ranging from about 2 to about 24 hours or longer |
| 05/29/2008 | US20080124392 venlafaxine hydrochloride; provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting |
| 05/29/2008 | US20080124391 Algal and algal extract dietary supplement composition |
| 05/29/2008 | US20080124390 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 05/29/2008 | US20080124389 Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine |
| 05/29/2008 | US20080124388 tannins obtained through total or semi-chemical syntheses; can sufficiently promote early growth of new blood vessels in the infarct zone to quickly restore the coronary blood circulation once an ischemic event occurs |
| 05/29/2008 | US20080124387 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| 05/29/2008 | US20080124386 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 05/29/2008 | US20080124385 Methods for Transmembrane Treatment and Prevention of Otitis Media |
| 05/29/2008 | US20080124384 Heteroaryl Substituted Piperazinyl-Pyridine Analogues |
| 05/29/2008 | US20080124383 Delivery to inflamed tissue by injection, implantation, or transdermal patch; prevention of pro-inflammatory cytokines will reduce and/or alleviate inflammation of tendons and soft tissue around carpal and tarsal tunnels; reducing compression of the median nerve and posterior tibial nerve, respectively |
| 05/29/2008 | US20080124382 Packaging two different substrates |
| 05/29/2008 | US20080124381 sufficient film strength and rapid disintegration profiles; high and low molecular weight water soluble polymer, an active agent, hydroxypropyl methylcellulose, hydroxypropyl cellulose |
| 05/29/2008 | US20080124378 for delivering a drug through contact with an eye; treatment of large animals, such as horses |
| 05/29/2008 | US20080124377 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 05/29/2008 | US20080124376 Ocular devices and methods of making and using thereof |
| 05/29/2008 | US20080124375 Device and Methods of Sequential, Regional Delivery of Multiple Cyctotoxic Agents and Directed Assembly of Wound Repair Tissues |
| 05/29/2008 | US20080124350 Nanoparticle-based vaccine delivery system containing adjuvant |
| 05/29/2008 | US20080124314 Peptide inhibitors of cyclin-dependent kinase activity and uses thereof |
| 05/29/2008 | US20080124283 Method of Providing Fast Relief to a User of a Nicotine Chewing Gum |
| 05/29/2008 | US20080124280 Thyroid Hormone Analogs and Methods of Use |
| 05/29/2008 | US20080124279 pectin is crosslinked with a metal cation; drug delivery system; treating colon cancer; orally administrable |
| 05/29/2008 | US20080124272 antibodies against influenza neuraminidase antigens; monoclonal antibody or antigen binding fragment |
| 05/29/2008 | DE102006055693A1 Beschichtung von Ballonkathetern zur gleichmäßigen Abgabe von Medikamenten Coating of balloon catheters for uniform delivery of drugs |
| 05/29/2008 | CA2749074A1 Process for the preparation of sevelamer hydrochloride and formulation thereof |
| 05/29/2008 | CA2672876A1 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof |
| 05/29/2008 | CA2670454A1 Delivery system for a non-steroidal non-ionized hydrophilic drug |
| 05/29/2008 | CA2670290A1 Transdermal therapeutic system for administering the active substance buprenorphine |
| 05/29/2008 | CA2670157A1 Delivery system for risperidone |
| 05/29/2008 | CA2670155A1 Stable powder formulation containing an anticholinergic agent |
| 05/29/2008 | CA2670153A1 Stable powder formulation containing a novel anticholinergic agent |
| 05/29/2008 | CA2669846A1 Materials and methods for introducing genetic material into living cells |
| 05/29/2008 | CA2669833A1 Vaginal delivery system for mirtazapine |
| 05/29/2008 | CA2669705A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 05/29/2008 | CA2669616A1 Devices, systems and methods for medicament delivery |
| 05/29/2008 | CA2669410A1 Modified release analgesic suspensions |
| 05/29/2008 | CA2669308A1 Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 05/29/2008 | CA2669094A1 Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| 05/29/2008 | CA2669066A1 Helically-shaped drug delivery system |
| 05/29/2008 | CA2667494A1 Dual action, inhaled formulations providing both an immediate and sustained release profile |
| 05/29/2008 | CA2665726A1 Pharmaceutical compositions |
| 05/29/2008 | CA2662510A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |